Table 1.
Demographic characteristics of the study population.
| No AECOPD | AECOPD | P-value | |
|---|---|---|---|
| Sample size | 306 | 138 | |
| Monocyte% | 8.6(6.7,10.4) | 8.7(6.5,11.2) | 0.605 |
| Low at < 7.5% | 95(31.05%) | 51(36.96%) | 0.003 |
| Medium at 7.5 to < 10% | 117(38.24%) | 30(21.74%) | |
| High at ≥ 10% | 94(30.72%) | 57(41.3%) | |
| Monocyte count | 60.62(44.16,79.92) | 67.08(51.12,94.01) | 0.004 |
| FEV1_post | 1.43(1.06,1.85) | 1.23(0.87,1.63) | 0.001 |
| FEV1_post% | 61.95(47.9,75.5) | 53.9(39.5,66.8) | < 0.001 |
| FEV1/FVC_post% | 61.13(52.66,67.12) | 59.53(50.28,65.27) | 0.035 |
| CAT | 3(2,5) | 5(4,8) | < 0.001 |
| ≤ 10 | 303(99.02%) | 128(92.75%) | < 0.001 |
| > 10 | 3(0.98%) | 10(7.25%) | |
| MMRC | 2(1,2) | 2(1,2) | 0.110 |
| 0 | 36(11.76%) | 5(3.62%) | 0.055 |
| 1 | 100(32.68%) | 48(34.78%) | |
| 2 | 144(47.06%) | 73(52.9%) | |
| ≥ 3 | 26(8.5%) | 12(8.7%) | |
| Gender, Male | 270(88.24%) | 124(89.86%) | 0.617 |
| Age | 72(65,81) | 74(67,81) | 0.383 |
| Cough | 150(49.02%) | 100(72.46%) | < 0.001 |
| Dyspnea | 116(37.91%) | 78(56.52%) | < 0.001 |
| Wheeze | 95(31.05%) | 84(60.87%) | < 0.001 |
| Chest tight | 43(14.05%) | 21(15.22%) | 0.746 |
| Chest pain | 24(7.84%) | 14(10.14%) | 0.422 |
| HPT | 144(47.06%) | 82(59.42%) | 0.047 |
| DM | 68(22.22%) | 39(28.26%) | 0.317 |
| Hyperlipidemia | 74(24.18%) | 33(23.91%) | 0.795 |
| CHF | 15(4.9%) | 17(12.32%) | 0.016 |
| CPD | 157(51.31%) | 96(69.57%) | < 0.001 |
| Heart failure | 50(16.34%) | 27(19.57%) | 0.572 |
| Sleep disorder | 99(32.35%) | 61(44.2%) | 0.016 |
| malignancy | 44(14.38%) | 30(21.74%) | 0.128 |
| Pneumonia | 34(11.11%) | 37(26.81%) | < 0.001 |
| Eosinophil | 1.7(0.8,3.4) | 1.45(0.5,3.5) | 0.495 |
| Lymphocyte | 21.3(13.4,30) | 19.8(11,28.5) | 0.106 |
| Neutrophil | 65(56.3,76.1) | 67.3(55.8,79.3) | 0.353 |
| Eosinophil to Lymphocyte | 0.08(0.04,0.15) | 0.08(0.03,0.18) | 0.927 |
| < 0.049 | 110(35.95%) | 40(28.99%) | 0.357 |
| 0.049 to < 0.122 | 98(32.03%) | 49(35.51%) | |
| > = 0.122 | 98(32.03%) | 49(35.51%) | |
| Neutrophil to Lymphocyte | 3(1.88,5.63) | 3.34(1.98,7.21) | 0.146 |
| Platelet count | 205.5(162,246) | 195.5(161,237) | 0.368 |
| WBC count | 7(5.6,9.1) | 7.95(6.4,10.3) | < 0.001 |
| RBC count | 4.51(4.09,4.86) | 4.55(4.22,4.86) | 0.260 |
| Hb | 13.75(12.2,15) | 13.9(12.8,15) | 0.358 |
| RDW | 13.85(13.3,14.5) | 13.9(13.4,14.7) | 0.540 |
| pH | 6.68(6,7.32) | 7(6,7.38) | 0.428 |
| Basophil | 0.5(0.4,0.8) | 0.6(0.4,0.8) | 0.849 |
| MPV | 8(7.4,8.6) | 8.1(7.5,8.9) | 0.306 |
| CRP | 0.77(0.13,3.85) | 0.62(0.14,4.21) | 0.828 |
| COPD medication within 6 months | |||
| Mono- therapy | 46(15.03%) | 25(18.12%) | 0.412 |
| Dual- therapy | 191(62.42%) | 95(68.84%) | 0.191 |
| Triple- therapy | 51(16.67%) | 46(33.33%) | < 0.001 |
| Oral long-acting bronchodilators | 14(4.58%) | 21(15.22%) | < 0.001 |
| Methylxanthines | 182(59.48%) | 108(78.26%) | < 0.001 |
| SBP | 133.8(125,145.4) | 133(124,145) | 0.973 |
| DBP | 75(68,81) | 76(70,82) | 0.289 |
| Pulse rate | 83(75,92) | 84(74,95) | 0.650 |
| Breathing | 18(18,20) | 18(18,19) | 1.000 |
| BMI | 23.82(21.21,26.17) | 23.38(21.19,26.01) | 0.490 |
| Smoking status | |||
| Never smoker | 66(21.57%) | 27(19.57%) | 0.605 |
| Former smoker | 194(63.4%) | 94(68.12%) | |
| Current smoker | 46(15.03%) | 17(12.32%) | |